Other languages Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Market Closed - Japan Exchange Other stock markets 07:00:00 27/06/2024 BST			5-day change	1st Jan Change
6,256 ^JPY	+0.08%		+2.12%	-7.97%

06-25	Japanese Shares Close Higher as Officials Address Yen Volatility Concerns	MT
06-25	Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Japanese Shares Close Higher as Officials Address Yen Volatility Concerns	06-25
Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan	06-25
Japan's Nikkei little changed ahead of key US data, central bank meetings	06-07
Japan's Nikkei edges down ahead of key US data, central bank meetings	06-07
Japan's Nikkei drifts sideways as more earnings, US CPI awaited	05-14
MÄRKTE ASIEN/Börsen wenig verändert - Mazda sehr schwach	05-13
MÄRKTE ASIEN/Uneinheitlich - Anleger meiden Risiken vor US-Preisdaten	05-13
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial	05-13
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	04-30
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	04-25
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	04-18
Shionogi Completes Up to 75 Billion Yen Share Buyback	03-29
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	03-07
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	03-06
GSK says ViiV's cabotegravir study supports longer HIV dose interval	03-05
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir	03-05
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	03-05
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs	03-04
GSK's new HIV drug formula could support longer dosing intervals (March 4)	03-04
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval	03-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Other languages

Filters